Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 110605
- Cleveland
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient is enrolled in the BAY94-9027 extension studies or is within 3 months of having completed participation in the BAY94-9027 extension studies;
Patient allocated to Arm 2, Arm 3 or Arm 4 of BAY94-9027 extension studies.
- Arm 2 Prophylaxis treatment of BAY94-9027; 2 infusions per week during the extension study
- Arm 3 Prophylaxis treatment of BAY94-9027; infusion every 5 days during the extension study
- Arm 4 Prophylaxis treatment of BAY94-9027; every 7 days during the extension study
- Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study;
- Patient must be willing and able to participate in a telephone interview lasting up to 30 minutes;
- Patient must have sufficient cognitive and linguistic capacities to allow them to actively participate in an interview lasting 30 minutes.
Exclusion Criteria:
- Patient is part of Arm 1: On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds;
- Patient is unlikely to comply with the study protocol (e.g. uncooperative attitude) or unlikely to complete the study for any reason in the opinion of the recruiter;
- Patient has great difficulty hearing or reading;
- Patient has any significant comorbid condition (including uncontrolled psychiatric conditions) that might limit or interfere with their ability to talk about their Hemophilia A and participate in the study;
- Patient has severe neurological or cognitive deficits that might affect their ability to participate in an interview.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Prophylaxis treatment of BAY94-9027_1
2 infusions per week during the extension study
|
Intravenous infusion of BAY94-9027
|
|
Prophylaxis treatment of BAY94-9027_2
infusion every 5 days during the extension study
|
Intravenous infusion of BAY94-9027
|
|
Prophylaxis treatment of BAY94-9027_3
every 7 days during the extension study
|
Intravenous infusion of BAY94-9027
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Qualitative interviews (with patients) to determine patients' satisfaction
Time Frame: up to 4 months
|
To conduct qualitative interviews with patients with Hemophilia A who have participated in the BAY94-9027 extension studies to evaluate patient experiences of and perspectives regarding their current treatment and the extent to which the frequency of FVIII infusions (compared to previous treatments) influences satisfaction
|
up to 4 months
|
|
Qualitative interviews (with patients) to determine patients' quality of life
Time Frame: up to 4 months
|
To conduct qualitative interviews with patients with Hemophilia A who have participated in the BAY94-9027 extension studies to evaluate patient experiences of and perspectives regarding their current treatment and the extent to which the frequency of FVIII infusions (compared to previous treatments) influences quality of life;
|
up to 4 months
|
|
Qualitative interviews (with treating physicians) to determine patients' satisfaction
Time Frame: up to 4 months
|
To conduct qualitative interview with clinicians who treat patients with Hemophilia A who have participated in the BAY94-9027 extension studies to evaluate the clinician perspective of patient experiences of and perspectives regarding their current treatment and the extent to which the frequency of FVIII infusions (compared to previous treatments) influences their patients' satisfaction
|
up to 4 months
|
|
Qualitative interviews (with treating physicians) to determine patients' quality of life
Time Frame: up to 4 months
|
To conduct qualitative interview with clinicians who treat patients with Hemophilia A who have participated in the BAY94-9027 extension studies to evaluate the clinician perspective of patient experiences of and perspectives regarding their current treatment and the extent to which the frequency of FVIII infusions (compared to previous treatments) influences their patients' quality of life;
|
up to 4 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 19144
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.